rocaglamide and Carcinoma--Non-Small-Cell-Lung

rocaglamide has been researched along with Carcinoma--Non-Small-Cell-Lung* in 2 studies

Other Studies

2 other study(ies) available for rocaglamide and Carcinoma--Non-Small-Cell-Lung

ArticleYear
Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy.
    Autophagy, 2018, Volume: 14, Issue:10

    Targeting macroautophagy/autophagy is a novel strategy in cancer immunotherapy. In the present study, we showed that the natural product rocaglamide (RocA) enhanced natural killer (NK) cell-mediated lysis of non-small cell lung cancer (NSCLC) cells in vitro and tumor regression in vivo. Moreover, this effect was not related to the NK cell recognition of target cells or expressions of death receptors. Instead, RocA inhibited autophagy and restored the level of NK cell-derived GZMB (granzyme B) in NSCLC cells, therefore increasing their susceptibility to NK cell-mediated killing. In addition, we further identified that the target of RocA was ULK1 (unc-51 like autophagy activating kinase 1) that is required for autophagy initiation. Using firefly luciferase containing the 5ยด untranslated region of ULK1, we found that RocA inhibited the protein translation of ULK1 in a sequence-specific manner. Taken together, RocA could block autophagic immune resistance to NK cell-mediated killing, and our data suggested that RocA was a promising therapeutic candidate in NK cell-based cancer immunotherapy.

    Topics: Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Benzofurans; Carcinoma, Non-Small-Cell Lung; Cell Degranulation; Granzymes; Humans; Killer Cells, Natural; Lung Neoplasms; Male; Mice, Inbred C57BL; Mice, SCID; Models, Biological; Protein Biosynthesis; Receptors, Death Domain

2018
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Oncogene, 2017, 08-17, Volume: 36, Issue:33

    KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a direct RAS effector protein, is required for KRAS-mediated tumourigenesis. Thus, the molecular mechanisms driving the activation of CRAF are intensively studied. Prohibitin 1 (PHB1) is an evolutionarily conserved adaptor protein and interaction of CRAF with PHB1 at the plasma membrane is essential for CRAF activation. Here, we demonstrate that PHB1 is highly expressed in NSCLC patients and correlates with poor survival. Targeting of PHB1 with two chemical ligands (rocaglamide and fluorizoline) inhibits epidermal growth factor (EGF)/RAS-induced CRAF activation. Consistently, treatment with rocaglamide inhibited proliferation, migration and anchorage-independent growth of KRAS-mutated lung carcinoma cell lines. Surprisingly, rocaglamide treatment inhibited Ras-GTP loading in KRAS-mutated cells as well as in EGF-stimulated cells. Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models. Our results suggest rocaglamide as a RAS inhibitor and that targeting plasma membrane-associated PHB1 with chemical ligands would be a viable therapeutic strategy to combat KRAS-mediated NSCLCs.

    Topics: Animals; Benzofurans; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; EGF Family of Proteins; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Molecular Targeted Therapy; Prohibitins; Proto-Oncogene Proteins p21(ras); raf Kinases; ras Proteins; Repressor Proteins; Signal Transduction; TNF Receptor-Associated Factor 3; Xenograft Model Antitumor Assays

2017